Cargando…

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future

SIMPLE SUMMARY: The assessment of responses is critical in patients diagnosed with multiple myeloma. Nowadays, one of the most informative parameters to discriminate responses to treatment and prognosis is minimal residual disease (MRD). Several strategies may be used to detect and quantify MRD; som...

Descripción completa

Detalles Bibliográficos
Autores principales:	Medina-Herrera, Alejandro, Sarasquete, María Eugenia, Jiménez, Cristina, Puig, Noemí, García-Sanz, Ramón
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377959/ https://www.ncbi.nlm.nih.gov/pubmed/37509348 http://dx.doi.org/10.3390/cancers15143687

Ejemplares similares

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
por: Ackley, James, et al.
Publicado: (2021)

Oncolytic Virotherapy for Multiple Myeloma: Past, Present, and Future
por: Thirukkumaran, Chandini M., et al.
Publicado: (2011)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
por: Mina, Roberto, et al.
Publicado: (2020)

Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
por: Elbezanti, Weam Othman, et al.
Publicado: (2023)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
por: Kostopoulos, Ioannis V., et al.
Publicado: (2020)

DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma
por: Quwaider, Dalia, et al.
Publicado: (2017)

Antibiotic residues in milk: Past, present, and future
por: Sachi, Sabbya, et al.
Publicado: (2019)

Minimal residual disease in multiple myeloma: are we there yet?
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

Minimal residual disease in multiple myeloma: current status
por: Ding, Hong, et al.
Publicado: (2021)

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
por: Flores-Montero, J, et al.
Publicado: (2017)

Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma: Past, Present, and Future
por: Ozaki, Shuji, et al.
Publicado: (2014)

Past, Present, and Future of Minimally Invasive Abdominal Surgery
por: Antoniou, Stavros A., et al.
Publicado: (2015)

Minimal-Access Coronary Revascularization: Past, Present, and Future
por: Purmessur, Rushmi, et al.
Publicado: (2023)

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
por: Nishihori, Taiga, et al.
Publicado: (2016)

Measurable residual disease in multiple myeloma: ready for clinical practice?
por: Burgos, Leire, et al.
Publicado: (2020)

Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
por: Charalampous, Charalampos, et al.
Publicado: (2022)

B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients
por: Mendonça de Pontes, Robéria, et al.
Publicado: (2021)

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
por: Medina, Alejandro, et al.
Publicado: (2020)

MINIMAL RESIDUAL DISEASE IN PERIPHERAL BLOOD ASSESSED BY MASS SPECTROMETRY
por: Puig, Noemi
Publicado: (2022)

Minimally Invasive Surgery for Colorectal Cancer: Past, Present, and Future
por: Holder-Murray, J., et al.
Publicado: (2011)

Quality and Safety of Minimally Invasive Surgery: Past, Present, and Future
por: McCrory, Bernadette, et al.
Publicado: (2014)

Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients
por: Zamagni, Elena, et al.
Publicado: (2020)

Minimal Residual Disease in Multiple Myeloma: Something Old, Something New
por: Bravo-Pérez, Carlos, et al.
Publicado: (2021)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium
por: Krzywdzińska, Agnieszka, et al.
Publicado: (2021)

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
por: Yao, Qiumei, et al.
Publicado: (2019)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum
por: Tapia-Alveal, Claudia, et al.
Publicado: (2020)

Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma
por: GOZZETTI, ALESSANDRO, et al.
Publicado: (2023)

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
por: Romano, Alessandra, et al.
Publicado: (2019)

Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression
por: Díaz-Tejedor, Andrea, et al.
Publicado: (2021)

Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma
por: Foureau, David, et al.
Publicado: (2021)

Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma
por: Foureau, David M., et al.
Publicado: (2023)

Multiple sclerosis in Isfahan, Iran: Past, Present and Future
por: Etemadifar, Masoud, et al.
Publicado: (2012)

Bilirubin 2022: The Past, the Present and the Future
por: Bellarosa, Cristina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j2esm1sree9pfmetil9dtsqid4